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Introduction: RNA-dependent protein kinase (PKR) is an indepen-
dent prognostic variable in patients with non–small-cell lung cancer 
(NSCLC). In the current study, we investigated the correlation between 
PKR and 25 other biomarkers for NSCLC, identified the markers that 
could further improve the prognostic significance of PKR and eluci-
dated the mechanisms of interaction between these markers and PKR.
Methods: Tissue microarray samples obtained from 218 patients 
with lung cancer were stained with an anti-PKR antibody and anti-
bodies against 25 biomarkers. Immunohistochemical expression was 
scored and used for Kaplan–Meier survival analysis. The interaction 
between PKR and EphA2 in NSCLC cell lines was examined.
Results: We found that PKR was associated with EphA2 and that 
the prognostic information regarding NSCLC provided by the com-
bination of PKR and EphA2 (P/E) was significantly more accurate 
than that provided by either marker alone. The 5-year overall survival 
rate in patients with PKRlow/EphA2high (20%) was significantly lower 
than that of patients with PKRhigh/EphA2low (74%) , patients with 
PKRhigh/EphA2high (55%) , and patients with PKRlow/EphA2low (55%) 
(p < 0.0001). We also found that the PKR:EphA2 (P/E) ratio was 
significantly associated with prognosis (p < 0.0001). Univariate and 
multivariate Cox analyses revealed that this P/E combination or ratio 
was an independent predictor of overall survival. In addition, induc-
tion of PKR expression reduced EphA2 protein expression levels in 
NSCLC cell lines.
Conclusions: PKR/EphA2 is a significant predictor of prognosis 
for NSCLC. PKR/EphA2 may be a promising approach to improv-
ing screening efficiency and predicting prognosis in patients with 
NSCLC.
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The progression of non–small-cell lung cancer (NSCLC) is driven by a variety of cell signaling pathways. NSCLC 
is molecularly heterogeneous, leading to differences in 
clinical outcome and requires the identification of multiple 
biomarkers of NSCLC to accurately predict outcome.1,2 
One potential biomarker of NSCLC is RNA-dependent 
protein kinase (PKR), a serine/threonine kinase initially 
identified as an innate immune antiviral protein that has a 
role in other cellular functions, including apoptosis, growth 
regulation, cell proliferation, and inflammation.3–7 We 
previously demonstrated that a PKR pathway is necessary for 
induction of cell death in various cancer cells after different 
treatments.8–11 In addition, autophosphorylated PKR can 
catalyze the phosphorylation of target substrates of eIF2α, 
thereby dramatically inhibiting protein synthesis, inducing 
apoptosis, and increasing the expression of proapoptotic 
factors such as Fas.3,4 PKR may have a role as a tumor 
suppressor in patients with leukemia or other hematologic 
malignancies.12–14 PKR is a prognostic marker of several 
human cancers, including lung, liver, colon, and head 
and neck cancers.15,16 What’s more, high PKR expression 
predicts favorable outcomes in patients with lung cancer.17,18 
New biomarkers that can further improve the prognostic 
significance of PKR must, however, be identified.
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In the current study, we used immunohistochemi-
cal analysis to investigate the association between PKR and 
25 biomarkers and found that the combination of PKR and 
EphA2 is a significantly more accurate prognostic indicator 
for NSCLC than either marker alone. EphA2 expression is 
frequently elevated in several different types of cancer cells, 
including lung, breast, colon, esophageal, ovarian, pancreatic, 
and prostate cancer cells.19,20 High EphA2 protein expres-
sion predicts poor survival and disease recurrence in patients 
with these cancers.21,22 These opposing functions of PKR and 
EphA2 led us to investigate the mechanisms of these two bio-
markers’ interaction in NSCLC cells.
PATIENTS AND METHODS
Patients and Tissue Samples
A total of 218 patients with NSCLC (119 adenocarcino-
mas and 99 squamous cell carcinomas) with stage I through IV 
disease who were undergoing resection of their primary can-
cer at The University of Texas MD Anderson Cancer Center 
between 1997 and 2001 were used for this study. Patients were 
excluded from the study if they had neoadjuvant or adjuvant 
therapy. The specimens of which were obtained from Lung 
Cancer Specialized Program of Research Excellence Tissue 
Bank at The University of Texas MD Anderson Cancer Center 
under a protocol approved by the MD Anderson Institutional 
Review Board.17,21,23 Detailed clinical and pathological infor-
mation, including demographic data, smoking history (never 
and ever smokers), pathological tumor, node, metastasis stage, 
and overall survival data, were available for all patients. The 
tissue samples were selected for tissue microarray (TMA) 
construction. TMAs were constructed using triplicate 1-mm–
diameter cores from each specimen.
Histopathologic Evaluation
Immunohistochemical staining for PKR and the other 25 
biomarkers was performed as described previously.17 Briefly, 
formalin-fixed and paraffin-embedded tissue histology sec-
tions (5 µm thick) were deparaffinized, hydrated, and heated 
in a steamer for 10 minutes with 10 mmol/liter of sodium 
citrate (pH 6.0) for antigen retrieval. Peroxide blocking was 
performed with 3% H
2
O
2
 in methanol at room temperature 
for 15 minutes, followed by 10% bovine serum albumin in 
TBS-t for 30 minutes. The slides were incubated with primary 
antibody at 1:400 dilution for 65 minutes at room tempera-
ture. After washing with phosphate-buffered saline, incuba-
tion with biotin-labeled secondary antibody for 30 minutes 
followed. Finally, the samples were incubated with a 1:40 
solution of streptavidin–peroxidase for 30 minutes. The stain-
ing was then developed with 0.05% 3′3-diaminobenzidine 
tetrahydrochloride prepared in 0.05 mol/liter of Tris buffer at 
pH 7.6 containing 0.024% H
2
O
2
 and then counterstained with 
hematoxylin. Formalin-fixed and paraffin-embedded lung tis-
sues with normal bronchial epithelia were used as a positive 
control. For a negative control, we used the same specimens 
used for the positive controls, replacing the primary antibody 
with phosphate-buffered saline.
Immunohistochemical expression was quantified by 
two independent pathologists (Drs Pataer and Raso) blinded 
to the patient treatment and outcome. Immunohistochemical 
 expression for TMA was quantified using a 4-value intensity 
score (0 for negative, 1 for weak, 2 for moderate, and 3 for 
strong), and the percentage of tumor cells within each category 
was estimated. A final score was obtained by multiplying both 
intensity and extension values (0 × % negative tumor cells + 
1 × % weakly stained tumor cells + 2 × % moderately stained 
tumor cells + 3 × % strongly stained tumor cells). The score 
ranged from a minimum of 0 to a maximum of 300. Cases with 
discordant scores between observers were reevaluated.
Cell Lines and Reagents
H1299 and H322 lung cancer cell lines were obtained 
from the American Type Culture Collection (Manassas, VA). 
Both H1299 and H322 cancer cells and their treatment with 
various adenovirus vectors have been well standardized in our 
laboratory. In addition, we have extensive experience in per-
forming in vivo gene transduction assays in these cell lines. 
We can transfected greater than 95% of these cells with vec-
tors. All cell lines were maintained in RPMI 1640 medium 
supplemented with 10% fetal bovine serum, 10-mM gluta-
mine, 100-U/ml penicillin, and 100-mg/ml streptomycin (Life 
Technologies, Inc., Grand Island, NY) in a 5% carbon dioxide 
atmosphere at 37°C.
A small interfering RNA (siRNA) targeting the EphA2 
receptor and a control nontargeting siRNA were obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). Ephrin-A1 
Fc and control Fc were obtained from R&D Systems 
(Minneapolis, MN). An anti-PKR (K-17) antibody was 
obtained from Santa Cruz Biotechnology. An anti–phosphor-
ylated PKR (p-PKR) (Thr446) antibody was obtained from 
Epitomics (Burlingame, CA); a mouse anti-EphA2 antibody 
(Clone D7) was obtained from Millipore (Billerica, MA); and 
a mouse anti–β-actin antibody, which was used as the control 
antibody, was obtained from Sigma (St. Louis, MO).
SiRNA Transfection
H1299 and H322 lung cancer cell lines were transfected 
with EphA2 siRNA or control nontargeting siRNA. Briefly, 
lung cancer cells were plated at a density of 2.0 × 105 cells per 
well in RPMI 1640 medium. Cells were treated with RPMI 
1640 medium 24 hours after plating. Transfected cells were 
incubated for a total of 96 hours at 37°C before western blot 
analysis.
Treatment of Ephrin-A1 for the Deregulation of 
EphA2 Expression
The cells were seeded in six-well plates (2 × 105 cells per 
well) in serum-deprived RPMI 1640 medium overnight and 
then stimulated with 1 μg/ml ephrin-A1 Fc or control Fc for 6 
or 24 hours. Cells were collected at the end of stimulation for 
western blot analysis.
Adenoviral Vector Transfection
For adenoviral vector transfection experiments, can-
cer cells were cultured at 70% confluence, transfected with 
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adenoviral luciferase or adenoviral wild-type PKR vectors 
for 72 hours and then evaluated for PKR protein expression 
through western blot analysis. Western blot analysis was per-
formed as described previously.9
Statistical Analysis
Biomarkers were assigned to either low- or high-level 
groups based on the median score (cutoff point for biomark-
ers). In the univariate analysis, continuous and categorical 
variables were analyzed using the independent samples t 
test and χ2 test, respectively. The Kaplan–Meier method was 
used to estimate survival probability as a function of time 
for the study patients. The log-rank test was used to measure 
between-group differences in patient survival time. The influ-
ence of biomarker expression on survival time was calculated 
using the multivariate Cox proportional hazards model with 
adjustment for clinical and histopathologic parameters (age, 
sex, smoking status, and tumor histologic subgroup). The two-
sided t test was used to test equal proportion between groups 
in two-way contingency tables. The generalized estimating 
equation approach was used to estimate differences in the 
means for the data between groups. Statistical significance 
was set at a p value of less than 0.05.
RESULTS
The Association between PKR and Protein  
Markers
Using TMAs and immunohistochemical analysis, we 
previously found that PKR expression was significantly asso-
ciated with overall survival in patients with stage I through 
IV NSCLC who had not received neoadjuvant or adjuvant 
therapy.17 Wistuba and colleagues performed expression stud-
ies of 25 different protein markers according to their inter-
est by using the same TMAs (Table 1).17,21,23 We next attempt 
to explore the correlation between PKR and these markers. 
We analyzed associations between PKR and known NSCLC 
markers and found that PKR protein expression was signifi-
cantly associated with DNA nucleotide methyltransferase 1 
(DNMT1), thyroid transcription factor 1 (TTF-1), and EphA2 
(Table 1).
Complementary Prognostic Value of PKR  
and Markers
We sought to determine whether DNMT1, TTF-1, and 
EphA2 markers provided prognostic information for NSCLC 
in addition to that provided by PKR. We analyzed the com-
binations of PKR and DNMT1, PKR and TTF-1, and PKR 
and EphA2 in patients with NSCLC. We combined PKR and 
each marker to stratify patients into four groups: high expres-
sion of both PKR and the biomarker (high/high); high PKR 
expression and low marker expression (high/low); low PKR 
expression and high marker expression (low/high); and low 
expression of both PKR and the biomarker (low/low). The sur-
vival curves of patients with NSCLC based on the expression 
of PKR and DNMT1 (Fig. 1A), TTF-1 (Fig. 1B), or EphA2 
(Fig. 1C) are shown in Figure 1. As PKR/EphA2 was asso-
ciated with the poorest survival durations in patients with 
NSCLC at stage I specifically (data not shown) and at all 
stages (Fig. 1C), we focus on the relationship and mechanism 
between PKR and EphA2.
We also stratified patients into three groups based on 
the combined PKR/EphA2 expression data: high PKR expres-
sion and low EphA2expression (high/low), low PKR expres-
sion and high EphA2 expression (low/high), and high or low 
expression of both proteins (others). Among patients with all 
stage of NSCLC, the 5-year overall survival rate in patients 
(20%) with PKRlow/EphA2high was significantly lower than that 
of patients (74%) with PKRhigh/EphA2low, patients (55%) with 
PKRhigh/EphA2high, and patients (55%) with PKRlow/EphA2low 
(Fig. 1D). Among patients with stage I NSCLC, the 5-year 
overall survival rate in patients (20%) with PKRlow/EphA2high 
was significantly lower than that in patients (81%) with 
PKRhigh/EphA2low, patients (61%) with PKRhigh/EphA2high, and 
patients (61%) with PKRlow/EphA2low (Fig. 1E). Our results 
also revealed that the PKR:EphA2 ratio was significantly 
associated with prognosis and was an independent indica-
tor of survival duration in patients with NSCLC at all stages 
(Fig. 1F, p < 0.0001) and at stage 1 (Fig. 1G, p < 0.0001). 
Immunohistochemical assays showed that both PKR and 
EphA2 proteins were primarily localized in the cytoplasm 
of tumor cells. Representative images of PKR and EphA2 
TABLE 1.  Correlation between PKR and Biomarkers on 
Patients with NSCLC
Marker Rho p Value
5T4 mem −0.05 0.55
BEK nuc −0.01 0.93
CAV-a cyt −0.03 0.79
Amphiregulin cyt −0.15 0.17
SOX2 cyt 0.04 0.68
CD24 cyt −0.03 0.79
CD44 cyt −0.06 0.56
EZH2 nuc 0.09 0.30
FEN1 nuc 0.16 .015
FLG nuc −0.07 0.52
HER3 cyt 0.14 0.09
HEY1 cyt −0.04 0.72
IL11R cyt 0.03 0.71
JNK mem 0.10 0.29
IRAK-1 nuc −0.07 0.51
Jagged1 cyt −0.02 0.85
NFKB nuc −0.09 0.26
SDC1 0.15 0.17
Her2/Neu nuc 0.13 0.12
RFC1 cyt 0.04 0.67
GLUT4 cyt 0.14 0.10
Ki67 nuc 0.09 0.27
DNMT1 cyt 0.41 <0.0001
TTF1 cyt 0.28 <0.0001
EphA2 cyt 0.45 <0.0001
Cyt, cytosol staining; mem, membrance staining; nuc, nuclear staining.
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expression in the cytoplasm of NSCLC cells are shown in 
Figure 1H and 1I.
Univariate Cox proportional hazards regression analysis 
revealed that age, pathologic tumor, node, metastasis stage, 
pathologic T classification, pathologic N classification, PKR 
expression, EphA2 expression, and PKR/EphA2 expression 
significantly affected overall survival (Table 2). Multivariate 
Cox proportional hazards regression analysis revealed that 
the expression of PKR or EphA2 was significantly associated 
with overall survival rate after accounting for the effects of 
age and pathologic T and N classification (data not shown) 
and that PKR/EphA2 was an independent prognostic predictor 
of overall survival rate (p < 0.0001) (Table 3). Univariate and 
multivariate Cox proportional hazards regression analysis 
revealed that the PKR:EphA2 ratio was an independent 
prognostic predictor of overall survival rate (data not shown). 
We next investigated the relationships between PKR:EphA2 
ratio and other clinicopathologic features. We did not detect 
any statistically significant correlations between PKR:EphA2 
ratio and patient’s gender (p = 0.2) and pathological stage 
(p = 0.39) (Table 4). We observed that higher PKR:EphA2 ratio 
was associated with the adenocarcinomas subtype (p = 0.003) 
FIGURE 1.  Prognostic significance of markers as assessed using Kaplan–Meier survival estimates and the log-rank test. Kaplan–
Meier survival curves showing the differences in survival duration using PKR combined with DNMT1 (A), TTF-1 (B), and EphA2 
(C) in patients with all stages of NSCLC. The survival rate in patients with PKRlow/EphA2high was significantly lower than that in 
patients with PKRhigh/EphA2low, patients with PKRhigh/EphA2high, and patients with PKRlow/EphA2low at all NSCLC stages (D) and at 
stage I (E). The PKR:EphA2 ratio was significantly associated with prognosis for NSCLC at all stages (F) and at stage I (G). The 
survival rate in the patients with a PKR:EphA2 ratio of 1.5 less was significantly lower than that in patients with a PKR:EphA2 
ratio of 1.5 or more than 1.5 (p < 0.0001). Immunohistochemical staining examples for the expressions of PKR (H) and EphA2 
(I) in the NSCLC cells cytoplasm (original magnification ×400). NSCLC, non–small-cell lung cancer; PKR, RNA-dependent pro-
tein kinase.
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and tobacco history (nonsmoker, p = 0.001). In previous report, 
we have demonstrated that PKR is closely associated with its 
phosphorylation (p-PKR), and patients with high expression 
of both PKR and p-PKR had significantly longer survival than 
did those with other combinations of expression levels.18 In the 
current study, we observed that higher PKR:EphA2 ratio was 
associated with the high p-PKR (phospho-PKR) expression 
(Table 4), and EphA2 protein expression negatively correlate 
with p-PKR protein expression (ρ = −0.41, p < 0.0001). We 
found that patients with high expression of both PKR and 
p-PKR had lower EphA2 expression and patients with high 
expression of PKR and low expression of p-PKR had higher 
EphA2 expression. Our data suggest that p-PKR and EphA2 
may negatively regulate each other in lung tumor.
PKR Induction Inhibits EphA2 
Protein Expression
As PKR has the strongest association with EphA2 
(Table 1), and PKR/EphA2 combination was associated with 
the poorest survival durations in patients with NSCLC (Fig. 
1C), we further investigated the mechanism of interaction 
between PKR and EphA2. We first determined whether knock-
down (depletion) of EphA2 by EphA2 siRNA in human lung 
cancer cells (H1299 and H322) causes induction or activation 
of PKR. Our results showed that knockdown of EphA2 expres-
sion by EphA2 siRNA in H1299 and H322 human lung cancer 
cells did not affect PKR or p-PKR protein levels (Fig. 2A).
We next determined whether inhibition of the Ras 
pathway by ephrin-A1 in NSCLC cells caused induction of 
PKR or p-PKR. Ephrin-dependent EphA2 activation inhibits 
Ras-Raf-MEK-ERK signaling by activating the RasGTPase-
activating protein, p120RasGAP, and down-regulates EphA2 
expression by causing receptor internalization and degra-
dation.24 Ephrin-A1, which is a major ligand for EphA2, is 
anchored to the plasma membrane by a glycosylphosphati-
dylinositol linkage, but soluble forms of this ligand released 
TABLE 2.  Univariate Cox Hazards Analysis Results for Overall 
Survival in Patients with NSCLC
Characteristic No. of  
patients
HR (95% CI) p Value
Age (continuous) 218 104 (1.02–1.06) <0.0001
Gender
 Female (Reference) 113 1.00
 Male 105 1.27 (0.89–1.81) 0.20
Histology
 Adenocarcinoma (Reference) 119 1.00
 Squamous cell carcinoma 99 1.50 (1.04–2.14) 0.03
Tobacco history
 No (Reference) 38 1.00
 Yes 180 1.56 (0.91–2.69) 0.11
Pathological stage 0.04
 IA/IB (Reference) 135 1.00
 IIA/IIB 47 1.20 (0.75–1.90) 0.45
 IIIA/IIIB 30 1.97 (1.20–3.26) 0.01
 IV 6 2.22 (0.81–6.1) 0.12
PKR
 Low (Reference) 108 1.00
 High 110 0.51 (0.36–0.74) <0.0001
EphA2
 Low (Reference) 116 1.00
 High 102 1.50 (1.05–2.15) 0.02
PKR/EphA2 <0.0001
 PKRH, EphA2L (Reference) 53 1.00
 PKRL, EPHA2H 45 3.47 (1.99–6.03) <0.0001
 Others 120 1.69 (1.03–2.75) 0.03
CI, confidence interval; HR, hazard ratio.
TABLE 3.  Multivariate Cox Hazards Analysis Results for 
Overall Survival in Patients with NSCLC
Characteristic No. of  
patients
HR (95% CI) p Value
Age (Continuous) 218 1.05 (1.03–1.07) <0.0001
Pathological stage 0.01
 IA/IB (Reference) 135 1.00
 IIA/IIB 47 1.24 (0.77–1.99) 0.37
 IIIA/IIIB 30 1.84 (1.11–3.05) 0.01
 IV 6 3.97 (1.41–11.21) 0.009
PKR/EphA2 <0.0001
 PKRH, EphA2L (Reference) 53 1.00
 PKRL, EphA2H 45 3.16 (1.8–5.55) <0.0001
 Others 120 1.84 (1.12–3.02) 0.01
CI, confidence interval; HR, hazard ratio.
TABLE 4.  Relationships between the PKR:EphA2 Ratio 
and Clinicopathologic Characteristics and Phospho-PKR 
Expression in 218 Patients with NSCLC
Characteristics Total No. (%)
PKR:EphA2 Ratio
p Value<1.5 (%) ≥1.5(%)
Gender
 Female 113 (52) 47 (45) 66 (58) 0.06
 Male 105 (48) 57 (55) 42 (42)
Histology
 Adenocarcinoma 119 (55) 46 (44) 73 (64) 0.003
 Squamous carcinoma 99 (45) 58 (56) 41 (36)
Tobacco history
 No 38 (17) 9 (9) 29 (25) 0.001
 Yes 180 (83) 95 (91) 85 (75)
Pathological stage
 IA/IB 135 (62) 63 (61) 72 (63) 0.39a
 IIA/IIB 47 (22) 24 (23) 23 (20)
 IIIA/IIIB 30 (14) 16 (15) 14 (12)
 IV 6 (2) 1 (1) 5 (5)
Phospho-PKR (p-PKR)
 High 78 (47) 27 (33) 51 (61) <0.0001b
 Low 87 (53) 54 (67 33 (39)
aThe p value was calculated between pathologic stage I and II–IV.
bTotal 165 patients have all three markers data (PKR, EphA2, and p-PKR).
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from the cell surface can also activate EphA2.24–26 Our experi-
ment revealed that degradation of EphA2 by ephrin-A1 Fc 
in H1299 and H322 lung cancer cells did not increase PKR 
or p-PKR expression (Fig. 2B). We next determined whether 
using expression vectors to induce PKR or p-PKR expression 
in lung cancer cells reduced EphA2 protein expression levels. 
Compared with control and adenoviral luciferase, adenoviral 
PKR inhibited EphA2 protein expression in H1299 and H322 
cancer cell lines 72 hours after treatment (Fig. 2C).
DISCUSSION
In a previous study, Wistuba and colleagues used 
TMAs to measure the expression of 25 protein markers in 
NSCLC samples.21,23 Using the same TMAs, we found that 
the loss of PKR expression was correlated with an aggressive 
disease course and that high PKR expression predicted a 
subgroup of patients with a better survival.17 In the current 
study, we investigated the association between PKR and the 
25 markers and sought to identify the markers that could 
provide prognostic information in addition to that provided by 
PKR. We found that PKR protein expression was significantly 
correlated with DNMT1, TTF-1, and EphA2 expression and 
that PKR/EphA2 expression was a significant predictor of 
overall survival duration in patients with NSCLC. We also 
found that the PKR:EphA2 ratio was an independent predictor 
of survival duration in patients with NSCLC.
The findings of the current study not only identify PKR/
EphA2 as a novel predictor of prognosis but also suggest 
that targeting PKR and/or EphA2 has therapeutic potential 
in patients with NSCLC. PKR’s phosphorylation of eIF2α 
inhibits protein synthesis in host NSCLC cells, thereby 
causing apoptosis.7,27,28 High PKR expression indicates a 
favorable prognosis for a variety of malignancies, suggesting 
that PKR plays an important role effecting apoptosis in cancer 
cells and suppressing tumor progression.28 We previously 
found that high PKR or p-PKR expression in NSCLC cells 
correlated with a favorable prognosis, which is consistent with 
previous observations that PKR activation is associated with 
apoptosis induction.8,9,11,17,29 Several compounds can induce 
PKR-dependent apoptosis in cancer cells,30,31 indicating that 
induction of expression or activation of PKR is one potential 
novel approach to treating cancer. EphA2 is detectable in many 
cancer cells, including ovarian, prostate, colon, and brain 
FIGURE 2.  Induction of PKR expression inhibited 
EphA2. A and B, Western blot analysis of PKR, p-PKR, 
and EphA2 protein expression in H1299 and H322 
cancer cells after knockdown of EphA2 expression 
by siRNA and ephrin A1Fc. Treatment with EphA2 
targeting siRNA (A) or 1 μg/ml ephrin A1Fc or Fc 
for 6 and 24 hours (B) did not affect PKR or p-PKR 
protein expression levels. C, control; A1Fc, ephrin 
A1Fc. Fc used as control. (C) Western blot analysis of 
PKR, p-PKR, and EphA2 protein expression in H1299 
and H322 cancer cells 72 hours after treatment with 
Ad-Luc (2500 viral particles/cell) and Ad-PKR (2500 
viral particles/cell). Ad-Luc, adenoviral luciferase; 
Ad-PKR, adenoviral PKR; PKR, RNA-dependent pro-
tein kinase.
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cancer cells.32 In recent one study, Ishikawa M et al. reported 
that higher expression of EphA2 and ephrin-A1 is related to 
favorable clinicopathological features in pathological stage 
I non–small-cell lung carcinoma.33 However, presence of 
EphA2 has been associated with poor prognosis in many 
patients with cancer.19–23,34 We anticipate that the PKR/EphA2 
biomarker can be used to identify patients with NSCLC who 
may benefit from antitumor therapy with EphA2 pathway 
inhibitors.
Recently, studies showed that MEDI-547, an EphA2 
targeted fully human multiclonal antibody (1C1) conjugate, 
had a significant role in inhibiting tumor growth in mouse 
xenograft and rat syngeneic models of prostate and 
endometrial cancers.35,36 Furthermore, some peptides can 
selectively bind to the ligand-binding domain of EphA2 and 
an ephrin A1–Pseudomonas aeruginosa exotoxin A conjugate 
have shown promise in delivering drugs to tumors.37 Use of 
the combination of a PKR activator and an EphA2 inhibitor 
may be a promising therapy for NSCLC. In the future, we 
will investigate the use of combination therapy for NSCLC 
targeting both PKR and EphA2.
An understanding of PKR/EphA2 protein interactions 
is vital to the study of lung cancer and clarifying their con-
tribution to prognosis. In the current study, we observed no 
significant changes in the expression of PKR or p-PKR in the 
NSCLC cells in which EphA2 expression was down-regu-
lated, which indicates that EphA2 may not inhibit expression 
of PKR directly. One potential route of indirect inhibition of 
PKR is the Ras-Raf-MEK-ERK pathway, which negatively 
regulates PKR and positively regulates the EphA2 path-
way.38–41 In the current study, however, treating NSCLC cells 
with ephrin-A1, which down-regulates both the EphA2 and 
Ras-Raf-MEK-ERK pathways,39 did not affect the expression 
of PKR or p-PKR, suggesting that the Ras pathway does not 
regulate PKR or EphA2 in these cells. We found that induc-
tion of expression of PKR by adenoviral expression of PKR 
inhibited expression of EphA2 protein in lung cancer cells. 
We observed that EphA2 protein expression positively cor-
relate with PKR and negatively correlate with phospho-PKR 
(p-PKR) proteins. The possible explanation for this association 
is that the high expression of EphA2 may stimulate negative 
feedback (PKR induction), and activation of PKR (p-PKR) 
by others inhibit EphA2 protein expression. We also suspect 
that PKR and EphA2 regulate several common downstream 
targets and that cancer cell growth depends on the balance 
of PKR/EphA2 protein expression. Further study is needed 
to identify common targets of PKR and EphA2 pathways in 
NSCLC tumors.
In conclusion, PKR/EphA2 is a significant predictor of 
prognosis in patients with NSCLC. Further studies of multiple 
NSCLC markers mayyield additional information about the 
prognostic significance of PKR/EphA2. PKR/EphA2 may be 
a promising approach to improving screening efficiency and 
predicting prognosis in patients with NSCLC. We observed 
that induction of PKR expression in lung cancer cells inhib-
ited EphA2 protein expression in vitro. The possible explana-
tion is that a high PKR:p-PKR ratio turns off protein synthesis, 
decreases EphA2 expression, and inhibits tumor growth.
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